Heather Biele

Viz.ai announced a collaboration with BIOS Clinical Trials Coordinating Center at Johns Hopkins University to facilitate patient enrollment for the NIH-funded Biomarker and Edema Attenuation in Intracerebral Hemorrhage study.According to a Viz release, the partnership will give BEACH research teams access to Viz Recruit software, the company’s clinical trial acceleration platform, which

Linus Health announced a collaboration with Goizueta Institute @Emory Brain Health and The Seavey Clinic at Emory Healthcare to implement digital cognitive assessments in primary care for early detection of Alzheimer’s disease.According to a Linus Health release, the digital health company will work with Emory University to evaluate and operationalize advanced digital technology to help

Visionary Optics has launched Europa Tangent, a new scleral lens that provides customizable design and a three-zone step-system for optimal fitting, the company announced in a company press release.

Stemedica Cell Technologies announced the launch of a phase 2b/3 clinical trial to assess the safety, efficacy and tolerability of a single IV injection of allogenic mesenchymal stem cells in patients with chronic ischemic stroke.According to a release from the company, the multicenter, randomized, double-blind study is expected to enroll approximately 300 individuals, who will be divided into

LinusBio announced it has raised over $16 million in Series A funding to deliver technology that combines genomics, the environment and biological response to help diagnose and monitor the progression of disorders such as ALS and autism.According to a release from LinusBio, the novel platform also aims to improve clinical trials by providing data comparable to more than 500 liquid biopsies or

Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal genetic disorder in children.According to a release from Myrtelle, early data from the first in-human study, which is being conducted at Dayton Children’s Hospital in Ohio, revealed that all eight

Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s disease, Parkinson’s disease and ALS, the biopharmaceutical company announced in a press release. “Our dedication to advancing new therapeutics to impact neurodegenerative diseases remains steadfast,” Athira President and CEO Mark Litton, PhD, said in the release.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease. According to a company press release, Biomind is currently developing novel pharmaceutical formulations of psychedelic molecules 5-Metoxi-N, N-dimethyltryptamine

Click Therapeutics announced it has received breakthrough device designation from the FDA for its digital therapeutic, CT-132, as an adjunctive preventive treatment for episodic migraines in those aged 18 years and older. “We are thrilled to receive this breakthrough designation as it will facilitate collaborative discussions with the FDA and help expedite the process of bringing a

The Vision Council has released its Focused Insights: Online vs. In-Person Buyers 2022 report, which details key similarities and differences between eye wear consumers, including demographic data, purchasing habits and vision care use. “While in-person prescription glasses buyers tend to spe…